Demonstrating Pharmaceutical Quality System Effectiveness and Driving Continual Improvement: Evidence-Based Risk Reduction

PDA J Pharm Sci Technol. 2018 May-Jun;72(3):338-345. doi: 10.5731/pdajpst.2017.008524. Epub 2018 Apr 18.


Product knowledge grows and evolves during the life of a product. In order to maintain a state of control and deliver product with consistent quality throughout its commercial life, continuous improvement and product lifecycle management become essential. The practical link between product and process knowledge, risk-based control strategies, and continual improvement and innovation can be made stronger through evidence-based risk reduction. This paper introduces the concept of evidence-based risk reduction within the continual improvement framework. It presents how regulatory relief and flexibility in post-approval change management and overall product lifecycle management can likely only be achieved via (1) effective application of science and risk-based concepts and (2) demonstrated effectiveness of the pharmaceutical quality system in assuring a state of control.

MeSH terms

  • Drug Industry / standards*
  • Knowledge
  • Quality Control
  • Risk Management
  • Risk Reduction Behavior*
  • Technology, Pharmaceutical / standards*